CALGARY, Feb. 13 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a broad pipeline of protein- based pharmaceutical and non-pharmaceutical products, announced today that Andrew Baum, President and CEO of SemBioSys, is scheduled to present an overview of the Company’s operations including an update on its proprietary oilbody-oleosin technology at the BIO CEO & Investor Conference (Biotechnology Industry Organization) on Tuesday February 14, 2006 at the Waldorf-Astoria in New York City. SemBioSys’ presentation is scheduled for 11:00 AM Eastern Time in the Duke of Windsor room.
Mr. Baum is also participating in a focus session on agricultural biotechnology to be held Tuesday February 14, 2006 at 9:00 AM Eastern Time, also in the Duke of Windsor room. The panel participants include Hugh Grant, Chairman, President and CEO, Monsanto Company; Graham Brookes, Director, PG Economics Ltd. and Dr. Richard Hamilton, CEO, Ceres Inc.
About SemBioSys Genetics Inc. (www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company focused on the development, commercialization and production of protein-based pharmaceuticals and non-pharmaceutical products based on its plant genetic engineering skills and proprietary oilbody-oleosin technology platform - the Stratosome(TM) Biologics System. Its two lead pharmaceutical product candidates are insulin and a developmental cardiovascular drug called Apo AI. It also has a series of non-pharmaceutical products addressing animal health, nutritional oils and human topical markets. SemBioSys currently has five major funded partnership agreements, including agreements with Martek Biosciences Corporation, Lonza Inc. and Arcadia Biosciences, Inc.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
SemBioSys Genetics Inc.
CONTACT: SemBioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:bauma@sembiosys.com, Internet: www.sembiosys.com;Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail: rmarshall@equicomgroup.com
